The nasal spray, Spravato has been approved by the FDA for treating depression.
The Johnson & Johnson nasal spray is now the first ever stand-alone therapy for treatment-resistant depression and is for adults with a major depressive disorder.
Faculty experts at the George Washington University are available to discuss Spravato and how it works. To schedule an interview with an expert, please contact Katelyn Deckelbaum at [email protected].
Tony Yang, is a professor in health policy at the George Washington University School of Nursing with a joint appointment at the Milken Institute School of Public Health in the Department of Health Policy and Management. He was previously an FDA Regulatory Science Fellow.
Tony Roberson, is an associate professor in the GW School of Nursing. He has authored numerous publications and presented at national and international conferences in the area of his research and clinical expertise, adolescent psychiatric mental health.
Rhonda Schwindt, is an associate professor of nursing at the GW School of Nursing. She leads efforts to prepare future nurse practitioners in providing affirming mental health care to transgender and gender-expansive patients.
Amir Afkhami is a psychiatry expert at the GW Milken Institute School of Public Health. His work focuses on psychiatric services and education, behavioral health policy and the mental health consequences of conflict.
-GW-